Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd2914910.26442/SG29149ArticlesСтатьиResearch ArticleNephroprotective in patients with metabolic syndrome: approaches to the appointment of antihypertensive drugsНефропротекция у больных с метаболическим синдромом: подходы к назначению антигипертензивных препаратовOstroumovaO DОстроумоваО Д

д-р мед. наук, проф. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова; проф. каф. клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова

ostroumova.olga@mail.ruZykovaA AЗыковаА А

канд. мед. наук, доц. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова

alexandra-z@mail.ruMaksimovM LМаксимовМ Л

д-р мед. наук, проф. каф. клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова

maksim_maksimov@mail.ruA.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России15062016132VOL 13, NO2 (2016)ТОМ 13, №2 (2016)778309042020Copyright ©; 2016, Consilium MedicumCopyright ©; 2016, ООО "Консилиум Медикум"2016Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/29149

In the article shows the questions of prevalence, diagnosis and prognostic significance of renal damage in metabolic syndrome. Discusses the pathogenetic mechanisms of development and progression of chronic kidney disease in individuals with obesity. Approaches to selection of antihypertensive drugs, advantages and limitations of the major classes of antihypertensive drugs in the treatment of metabolic syndrome, arterial hypertension combined with renal disease.

В статье рассмотрены вопросы распространенности, диагностики и прогностической значимости поражения почек при метаболическом синдроме. Обсуждаются патогенетические механизмы развития и прогрессирования хронической болезни почек у лиц с ожирением. Приведены подходы к выбору антигипертензивных препаратов, рассмотрены преимущества и ограничения основных классов антигипертензивных лекарственных средств при лечении метаболического синдрома, артериальной гипертонии в сочетании с поражением почек.

metabolic syndromeobesityhypertensionmicroalbuminuriaverapamilметаболический синдроможирениеартериальная гипертониямикроальбуминурияверапамилЧазова И.Е., Недогода С.В., Жернакова Ю.В. и др. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестн. 2014; IX (XXI), 1: 4-57.Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Кардиоваскулярная терапия и профилактика. 2009; 6 (Прил. 2): 1-29.Ford E.S, Giles W.H, Dietz W.H. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287 (3): 356-9.Ротарь О.П., Либис Р.А., Исаева Е.Н. и др. Распространенность метаболического синдрома в разных городах РФ. Рос. кардиол. журн. 2012; 2: 55-62.Mursu J, Virtanen J.K, Tuomainen T-P et al. Intake of fruits, berries and vegetables and the risk of type 2 diabetes: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998, 445-51.Toole J.F, Chambless L.E, Heiss G et al. Ann Epidemiol 1993; 3 (5): 500-3.Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологический вестн. 2015; 1: 3-30.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertans 2013; 31: 1281-357.Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201-7.Чазова И.Е., Мычка В.Б. Метаболический синдром. Кардиоваскулярная терапия и профилактика. 2003; 3: 32-8.Диагностика и лечение артериальной гипертензии. Российские рекомендации. 4-я редакция. Системные гипертензии. 2010; 7 (3): 5-26.Matsushita K, Mahmodi B.K, Woodward M et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estmated glomerular filtration rate. JAMA 2012; 307: 1941-51.Levey A.S, Eckardt K.U, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100.Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20: 353-5.De Leeuw P.W, Ruilope L.M, Palmer C.R et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-64.Sarnak M.J, Levey A.S, Schoolwerth A.C et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.Gerstein H.C, Mann J.F, Yi Q et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kid Dis 2004; 43 (Suppl. 1): S16-S33.Arnlov J, Evans J.C, Meigs J.B et al. Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.Hillege H.L, Fidler V, Diercks G.F et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.Ninomiya T, Perkovic V, de Galan B.E et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-21.Matsushita K, van der Velde M, Astor B.C et al. Association of estimated glomerular filtration rate and albuminuria with all - cause and cardiovascular mortality in general population cohorts: a collaborative meta - analysis. Lancet 2010; 375: 2073-81.Segura J, Ruilope L.M, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22: 1635-9.Rahman M, Pressel S, Davis B.R et al. Cardiovascular outcomes in high - risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-80.Сhen J, Muntner P, Hamm L et al. The metabolic syndrome and chronic kidney disease in U.S. Adults. Ann Intern Med 2004; 140: 167-74.Iseki K, Ikemiya Y, Kinjo K et al. Body mass index and the risk of development of end - stage renal disease in a screened cohort. Kidney Int 2004; 65 (5): 1870-6.Gelber R.P, Kurth T, Kausz A.T et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46: 871-80.Wang Y, Cheng Х et al. Aassociation between obesity and kidney diseases: A systematic review and meta - analysis. Kidney Int 2008; 73: 18-23.Сагинова Е.А., Галлямов М.Г., Северова М.М. Современные представления о поражении почек при ожирении. Клин. нефрология. 2010; 2.Wolf G. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184-202.Сагинова Е.А., Федорова Е.Ю., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. архив. 2006; 78 (5): 36-41.Despres J-P, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-20.Hall J.E, Brands M.W, Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999; 892: 91-107.Wicek A, Kokot F, Chudek J et al. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17: 191-5.Gunter W, Sheldon C, Han D.C et al. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11.Wolf G, Ziyadeh F.N. Leptin and renal fibrosis. Contrib Nephrol 2006; 151: 175-83.Stam F, van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal functionassociated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-45.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно - сосудистых заболеваний. Вестн. РАМН. 2003; 11: 50-5.Yuyun M, Alder A.I, Wareham N.J. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events. Curr Opin Nephrol Hypertens 2005; 14: 271-6.Kougias P, Chai H, Lin P.H et al. Adipocyte - derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005; 41: 691-8.Schiffrin E.L, Touyz R.M. From bedside to bench to bedside: role of reninangiotensinaldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435-H446.Touyz R.M, Schiffrin E.L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-52.Praga M, Hernandez E, Morales E et al. Clinical features and long - term outcome of obesity - associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16 (9): 1790-8.Blanco S, Vaquero M, Gomez-Guerrero C et al. Potential role of angiotensinconverting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005; 18 (4 Pt. 1): 557-65.Geluk C.A, Asselbergs F.W, Hillege H.L et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 2005; 26 (13): 1314-20.Asselbergs F.W, Dierks G.F.H, Hillege H.L et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-16.Mann J.F.E, Gerstein H.C, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.Kunz R, Friedrich C, Wolbers M, Mann J.F.E. Meta - analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin - Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008; 148: 30-48.Schmidt A.C, Graf C, Brixius K et al. Blood pressure - lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Inv 2007; 27 (12): 841-9.Marre M, Puig J.G, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22 (8): 1613-22.Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium Medicum. 2006; 8 (11): 113-7.Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158-65.Vestra M.D, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259-66.Robles N.R, Ocon J, Gomez C.F et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1):73-80.Остроумова О.Д., Максимов М.Л., Копченов И.И. Антагонист кальция третьего поколения лерканидипин: новые возможности в лечении артериальной гипертонии. Рациональная фармакотерапия в кардиологии. 2013; 1: 79-85.Ruggenenti P, Fassi A, Ilieva A.P et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19): 1941-51.Hemmelder M.H, de Zeeuw D, de Jong P.E. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non - diabetic renal disease. Nephrol Dial Transplant 1999; 14 (1): 98-104.Bakris G.l, Copley J.B, Vicknair N et al. Verapamil SR has similar nephroprotective properties to Lisinopril and is significantly better in comparison to atenolol. Kidney Int 1996; 50: 1641-59.Bakris G, Weir M, de Quattro V et al. Renal, hemodynamic and antiproteinuricresponce to an ACE inhibitor trandolapril or calcium antagonist verapamil alone or in fixed combination in patients with diabetic nephropathy: A randomized multicenter study. J Am Soc Nephrol 1996; 7: 1546-52.Versari D, Virdis A, Ghiadoni L et al. Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. Atherosclerosis 2009; 205 (1): 214-20.Goligorsky M.S, Chaimovitz C, Rapaport J et al. Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil. Kidney Int 1995; 27: 774-9.Khodneva Y et al. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res Clin Pract 2016. http://dx.doi.org/10.1016/j.diabres.2016.01.021Andersson D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non - insulin - dependent diabetes mellitus. Acta Med Scand 1981; 210 (1-2): 27-33.Libretti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press. Drugs 1993; 46 (Suppl. 2): 16-23.